A$1.38 0.0 2.2%
Last Trade - 5:16am
| Market Cap | £88.2m |
| Enterprise Value | £74.8m |
| Revenue | £81.7k |
| Position in Universe | 710th / 1899 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.01 | 1.49 | 0.047 | 13.8 | 0.39 | 0.15 | 1.00 | 59.4 | -40.7% | ||
| -12.8 | ||||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company engaged in developing drugs for neurological disorders. The Company develops therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. Its products include NNZ-2566 and NNZ-2591. Its lead product, NNZ-2566 (Trofinetide), is in Phase II trial for the treatment of Rett syndrome, Fragile X syndrome, moderate to severe Traumatic Brain Injury (TBI) and Concussion. Trofinetide is an analog of a molecule, which is derived from insulin-like growth factor-1 (IGF-1) and occurs naturally in the brain. Its NNZ-2591 product is in Pre-clinical and Phase I trial for the treatment of other neurological conditions. Its subsidiaries include Hamilton Pharmaceuticals Inc. and Neuren Pharmaceuticals Inc.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | December 17, 2001 |
| Public Since | February 3, 2005 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 117,608,108 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | SE 201 697 Burke Rd Camberwell, MELBOURNE, 3124, Australia |
| Web | http://www.neurenpharma.com/irm/content/default.aspx |
| Phone | +61 3 90920480 |
| Contact | () |
| Auditors | Grant Thornton |
As of 5:16am, shares in Neuren Pharmaceuticals are trading at A$1.38, giving the company a market capitalisation of £88.2m. This share price information is delayed by 15 minutes.
Shares in Neuren Pharmaceuticals are currently trading at A$1.38 and the price has moved by 0.37% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Neuren Pharmaceuticals price has moved by -23.59% over the past year.
Of the analysts with advisory recommendations for Neuren Pharmaceuticals, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Neuren Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Neuren Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:
Neuren Pharmaceuticals does not currently pay a dividend.
Neuren Pharmaceuticals does not currently pay a dividend.
Neuren Pharmaceuticals does not currently pay a dividend.
To buy shares in Neuren Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Neuren Pharmaceuticals are currently trading at A$1.38, giving the company a market capitalisation of £88.2m.
Here are the trading details for Neuren Pharmaceuticals:
Based on an overall assessment of its quality, value and momentum, Neuren Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Neuren Pharmaceuticals are currently priced at A$1.38. At that level they are trading at 0.13% discount to the analyst consensus target price of 0.00.
Analysts covering Neuren Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -0.083 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neuren Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been 8.62%. At the current price of A$1.38, shares in Neuren Pharmaceuticals are trading at 5.9% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Neuren Pharmaceuticals.
Neuren Pharmaceuticals's management team is headed by:
Here are the top five shareholders of Neuren Pharmaceuticals based on the size of their shareholding:
